Alzheimer's drug with modest benefits wins backing of FDA advisers

Sara Reardon

DOI: https://doi.org/10.1038/d41586-024-01726-w

IF: 64.8

2024-06-11

Nature

Abstract:Donanemab slows progression of symptoms, but questions linger about the durability of its effect. Donanemab slows progression of symptoms, but questions linger about the durability of its effect.

multidisciplinary sciences

What problem does this paper attempt to address?

New Alzheimer's drug clears FDA advisory vote despite unknowns

Jennifer Couzin-Frankel

DOI: https://doi.org/10.1126/science.adr0291

IF: 56.9

2024-06-15

Science

Abstract:Pivotal trial of Eli Lilly's donanemab leaves questions about how to prescribe it and minimize risks

multidisciplinary sciences
Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's

Tanya Song,Yunfei Wang,Bret David Silverglate,George T. Grossberg

DOI: https://doi.org/10.1080/17425255.2024.2357637

2024-05-22

Expert Opinion on Drug Metabolism & Toxicology

Abstract:Introduction Donanemab is a humanized monoclonal antibody that significantly reduces cerebral amyloid plaques in Alzheimer's Disease (AD). It can delay disease progression and cognitive decline, making it one of the most promising disease-modifying treatments in the current treatment landscape.

pharmacology & pharmacy,biochemistry & molecular biology,toxicology
Alzheimer's drug approvals create prescribing dilemmas

Jennifer Couzin-Frankel

DOI: https://doi.org/10.1126/science.adu2383

IF: 56.9

2024-11-01

Science

Abstract:Clinicians and patients weigh modest benefits of the antibodies against sometimes-serious side effects

multidisciplinary sciences
1978 Donanemab in early symptomatic Alzheimer’s Disease: Efficacy and safety in TRAILBLAZER-ALZ 2, Phase 3 Randomized Clinical Trial

M Mintun,C Ritchie,P Solomon,J R Sims,S Salloway,O Hansson,L G Apostolova,J A Zimmer,C D Evans,M Lu,P Ardayfio,J D Sparks,A M Wessels,S Shcherbinin,H Wang,E S M Nery,E C Collins,E B Dennehy,D A Brooks,D M Skovronsky,A Farquharson (Non-author presenter),

DOI: https://doi.org/10.1093/ageing/afad246.112

2024-01-01

Age and Ageing

Abstract:Abstract Introduction In TRAILBLAZER-ALZ donanemab (DONA) cleared brain amyloid plaques, significantly slowing disease progression in early symptomatic Alzheimer’s disease (ESAD). Methods: TRAILBLAZER-ALZ2 enrolled participants with ESAD and amyloid and tau pathology by positron-emission tomography, randomizing (multicenter) those with low/medium-tau (n=1182) and high-tau (n=552) (missing tau n=2). Participants (randomized double-blind,1:1) received DONA (n=860)/placebo (n=876) IV every 4w for 72w. DONA participants meeting amyloid clearance treatment completion criteria at 24/52w had blinded switched to placebo. Primary outcomes Integrated AD Rating Scale(iADRS) change from baseline at 76w in low/medium-tau or combined (low/medium- and high-tau) populations. Statistical testing allocated most power (80% α spend) to low/medium-tau population outcomes, with the remainder for combined population outcomes, including clinical and biomarker assessments. Results In the low/medium-tau population iADRS change at 76w: −6.02 (DONA) and −9.27 (placebo) (difference 3.25; 95%CI, 1.88-4.62; P<0.001), 35.1% slowing of disease progression. Change in Clinical Dementia Rating Scale (CDR)–Sum of Boxes: 1.20 (DONA) and 1.88 (placebo) (difference −0.67; 95% CI −0.95 to −0.40; P<0.001), 36.0% slowing. Participants receiving DONA experienced 38.6% less risk of progressing to next disease stage vs placebo over 76w (CDR-Global score, HR=0.61; P<0.001). Amyloid clearance at 24/52/76w: achieved in 34.2%/71.3%/80.1% DONA-treated participants. Significant, positive results were observed in the combined population. Serious AEs: 17.4% (DONA), and 15.8% (placebo), with 3 deaths among DONA patients who experienced serious amyloid-related imaging abnormalities (ARIA). AEs with DONA included ARIA-E (24.0%, 6.1% symptomatic); ARIA-H (31.4%); infusion-related reactions (8.7%). Conclusion DONA treatment significantly slowed clinical progression at 76w with a safety profile consistent with earlier studies. Presented: AAIC2023.

geriatrics & gerontology,gerontology
FDA Considers Alzheimer’s Drug Previously Abandoned for Lack of Effectiveness

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.l6164

2019-01-01

Abstract:An Alzheimer’s drug that failed in two phase III trials and was abandoned as valueless has been brought back to life after an intensive examination of the trial results showed that it just might work in patients with early stage disease if the dose is right. Aducanumab, developed by Biogen, joined a long list of failed Alzheimer’s treatments in March this year after the two trials found that it failed to slow the course of the disease. A similar drug from Eli Lilly also failed,1 leading analysts to conclude that the search for a treatment that was based on attacking amyloid plaques, the pathological signature of the disease, was doomed. The failure hit Biogen hard, as it had created big expectations for aducanumab. So, drug company analysts showed …
Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Ivelina Gueorguieva,Brian A. Willis,Laiyi Chua,Kay Chow,C. Steven Ernest,Sergey Shcherbinin,Paul Ardayfio,Garrett R. Mullins,John R. Sims

DOI: https://doi.org/10.1002/cpt.2875

2023-03-09

Clinical Pharmacology & Therapeutics

Abstract:Donanemab is an amyloid-targeting therapy that resulted in robust amyloid plaque reduction and slowed Alzheimer's disease (AD) progression compared with placebo in the phase II TRAILBLAZER-ALZ study (NCT03367403). The objectives of the current analyses are to characterize (i) the population pharmacokinetics of donanemab, (ii) the relationship between donanemab exposure and amyloid plaque reduction (response), and (iii) the relationship between donanemab exposure and amyloid-related imaging abnormalities with edema or effusions (ARIA-E). Model development included data from participants with mild cognitive impairment or mild to moderate dementia due to AD from the phase Ib study on donanemab (NCT02624778) and participants with early symptomatic AD from the TRAILBLAZER-ALZ study. The analysis showed donanemab has a terminal elimination half-life of 11.8 days. Body weight and antidrug antibody titer impact donanemab exposure but not the pharmacodynamic response. Maintaining a donanemab serum concentration above 4.43 μg/mL (95% confidence interval: 0.956, 10.4) is associated with amyloid plaque reduction. The time to achieve amyloid plaque clearance (amyloid plaque level < 24.1 Centiloids) varied depending on the baseline amyloid level, where higher baseline levels were associated with fewer participants achieving amyloid clearance. The majority of participants achieved amyloid clearance by 52 weeks on treatment. Apolipoprotein ε4 carriers, irrespective of donanemab serum exposure, were 4 times more likely than noncarriers to have an ARIA-E event by 24 weeks.

pharmacology & pharmacy
Lecanemab Questions

Stephen E Nadeau,Stephen E. Nadeau

DOI: https://doi.org/10.1212/wnl.0000000000209320

IF: 9.9

2024-04-09

Neurology

Abstract:The recently published results of the 18-month randomized controlled trial of lecanemab, reporting the efficacy of the drug in slowing the progression of early Alzheimer disease, quickly led to approval by the FDA and widespread acceptance of lecanemab treatment. However, there are a number of matters that deserve further consideration. The success of blinding was not assessed, even as infusion reactions and the cerebral pathology underlying amyloid-related imaging abnormalities could have signaled to many participants that they were on drug, potentially exerting a potent placebo effect. The value of the outcome to participants is not defined in the absolute terms necessary for clinical decision-making, and the difference attributable to lecanemab was between 18% and 46% of estimates of the minimal clinically important difference on the Clinical Dementia Rating Scale Sum of Boxes. The attenuation of change on the Alzheimer's Disease Assessment Scale-Cognitive 14 achieved by lecanemab at 18 months was 50% of that achieved by donepezil at 6 months. Lecanemab treatment imposes a high treatment burden. The fact that the burden commences at the initiation of lecanemab treatment, whereas the benefit accrues years later requires us to take into account value discounting over time, which would significantly reduce the benefit/burden ratio. Finally, treatment with monoclonal antibodies to cerebral amyloid has consistently been associated with progressive cerebral atrophy. At the least, these issues should be raised in treatment discussions with patients. They also suggest a need to very seriously reconsider how we evaluate clinical trial results preparatory to translating them into clinical practice. Some suggestions are provided.

clinical neurology
How donanemab data address the coverage with evidence development questions

Eric G. Klein,Krista Schroeder,Alette Wessels,Adam Phipps,Maureen Japha,Traci Schilling,Jennifer A. Zimmer

DOI: https://doi.org/10.1002/alz.13700

2024-02-09

Alzheimer s & Dementia

Abstract:The Centers for Medicare & Medicaid Services (CMS) established a class‐based National Coverage Determination (NCD) for monoclonal antibodies directed against amyloid for Alzheimer's disease (AD) with patient access through Coverage with Evidence Development (CED) based on three questions. This review, focused on donanemab, answers each of these CED questions with quality evidence. TRAILBLAZER‐ALZ registration trials are presented with supporting literature and real‐world data to answer CED questions for donanemab. TRAILBLAZER‐ALZ registration trials demonstrated that donanemab significantly slowed cognitive and functional decline in amyloid‐positive early symptomatic AD participants, and lowered their risk of disease progression while key safety risks occurred primarily within the first 6 months and then declined. Donanemab meaningfully improved health outcomes with a manageable safety profile in an early symptomatic AD population, representative of Medicare populations across diverse practice settings. The donanemab data provide the necessary level of evidence for CMS to open a reconsideration of their NCD. Highlights Donanemab meaningfully improved outcomes in trial participants with early symptomatic Alzheimer's disease. Comorbidities in trial participants were consistent with the Medicare population. Co‐medications in trial participants were consistent with the Medicare population. Risks associated with treatment tended to occur in the first 6 months. Risks of amyloid‐related imaging abnormalities were managed with careful observation and magnetic resonance imaging monitoring.

clinical neurology
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial

Michael J Pontecorvo,Ming Lu,Samantha C Burnham,Andrew E Schade,Jeffrey L Dage,Sergey Shcherbinin,Emily C Collins,John R Sims,Mark A Mintun

DOI: https://doi.org/10.1001/jamaneurol.2022.3392

2022-12-01

Abstract:Importance: Plasma biomarkers of Alzheimer disease may be useful as minimally invasive pharmacodynamic measures of treatment outcomes. Objective: To analyze the association of donanemab treatment with plasma biomarkers associated with Alzheimer disease. Design, setting, and participants: TRAILBLAZER-ALZ was a randomized, double-blind, placebo-controlled clinical trial conducted from December 18, 2017, to December 4, 2020, across 56 sites in the US and Canada. Exploratory biomarkers were prespecified with the post hoc addition of plasma glial fibrillary acidic protein and amyloid-β. Men and women aged 60 to 85 years with gradual and progressive change in memory function for at least 6 months were included. A total of 1955 participants were assessed for eligibility. Key eligibility criteria include Mini-Mental State Examination scores of 20 to 28 and elevated amyloid and intermediate tau levels. Interventions: Randomized participants received donanemab or placebo every 4 weeks for up to 72 weeks. The first 3 doses of donanemab were given at 700 mg and then increased to 1400 mg with blinded dose reductions as specified based on amyloid reduction. Main outcomes and measures: Change in plasma biomarker levels after donanemab treatment. Results: In TRAILBLAZER-ALZ, 272 participants (mean [SD] age, 75.2 [5.5] years; 145 [53.3%] female) were randomized. Plasma levels of phosphorylated tau217 (pTau217) and glial fibrillary acidic protein were significantly lower with donanemab treatment compared with placebo as early as 12 weeks after the start of treatment (least square mean change difference vs placebo, -0.04 [95% CI, -0.07 to -0.02]; P = .002 and -0.04 [95% CI, -0.07 to -0.01]; P = .01, respectively). No significant differences in plasma levels of amyloid-β 42/40 and neurofilament light chain were observed between treatment arms at the end of treatment. Changes in plasma pTau217 and glial fibrillary acidic protein were significantly correlated with the Centiloid percent change in amyloid (Spearman rank correlation coefficient [R] = 0.484 [95% CI, 0.359-0.592]; P < .001 and R = 0.453 [95% CI, 0.306-0.579]; P < .001, respectively) following treatment. Additionally, plasma levels of pTau217 and glial fibrillary acidic protein were significantly correlated at baseline and following treatment (R = 0.399 [95% CI, 0.278-0.508], P < .001 and R = 0.393 [95% CI, 0.254-0.517]; P < .001, respectively). Conclusions and relevance: Significant reductions in plasma biomarkers pTau217 and glial fibrillary acidic protein compared with placebo were observed following donanemab treatment in patients with early symptomatic Alzheimer disease. These easily accessible plasma biomarkers might provide additional evidence of Alzheimer disease pathology change through anti-amyloid therapy. Usefulness in assessing treatment response will require further evaluation. Trial registration: ClinicalTrials.gov Identifier: NCT03367403.
Landmark Alzheimer’s drug approval confounds research community

Asher Mullard

DOI: https://doi.org/10.1038/d41586-021-01546-2

IF: 64.8

2021-06-08

Nature

Abstract:Many scientists say there is not enough evidence that Biogen's aducanumab is an effective therapy for the disease. Many scientists say there is not enough evidence that Biogen's aducanumab is an effective therapy for the disease.

multidisciplinary sciences
Donanemab in Early Alzheimer's Disease

Mark A Mintun,Albert C Lo,Cynthia Duggan Evans,Alette M Wessels,Paul A Ardayfio,Scott W Andersen,Sergey Shcherbinin,JonDavid Sparks,John R Sims,Miroslaw Brys,Liana G Apostolova,Stephen P Salloway,Daniel M Skovronsky,Mark A. Mintun,Albert C. Lo,Alette M. Wessels,Paul A. Ardayfio,Scott W. Andersen,John R. Sims,Liana G. Apostolova,Stephen P. Salloway,Daniel M. Skovronsky

DOI: https://doi.org/10.1056/NEJMoa2100708

2021-03-15

Abstract:This article was published on March 13, 2021, at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.
Lecanemab's Path Forward: Navigating the Future of Alzheimer's Treatment in Europe Amidst the EMA's Rejection

Alessandro Martorana,Chiara Giuseppina Bonomi,Martina Gaia Di Donna,Caterina Motta

DOI: https://doi.org/10.1007/s40120-024-00675-w

2024-11-04

Neurology and Therapy

Abstract:Lecanemab (Leqembi © , Biogen), a humanized anti-amyloid-beta monoclonal antibody, has been approved for early-stage Alzheimer's disease (AD) in several countries, including the US and Japan. However, the European Medicines Agency (EMA) recently issued a negative opinion on its marketing authorization, reflecting concerns over the clinical value and manageability of anti-amyloid treatments. This decision highlights the ongoing disconnect between research advancements and clinical practice, where the focus on biological markers over tangible clinical improvements remains contentious. Despite promising biological effects, lecanemab's clinical outcomes have been modest, raising questions about its therapeutic role. The EMA's refusal underscores the need to address doubts surrounding the real-world effectiveness and safety of such treatments, especially concerning amyloid-related imaging abnormalities (ARIAs), a common side effect observed in clinical trials. The recent approval of lecanemab by the UK's Medicines and Healthcare products Regulatory Agency, despite the National Institute for Health and Care Excellence's rejection on cost-effectiveness grounds, further fuels the debate on the feasibility of anti-amyloid therapies. This commentary emphasizes the importance of real-world data on lecanemab's impact on cognitive decline, daily functioning, and side-effect management. As the global clinical use of lecanemab increases, continuous and standardized reporting on its outcomes is crucial for guiding future regulatory decisions and for potentially bridging the gap between research and practice in AD treatment.

clinical neurology
Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies

Leonardino A. Digma MD,Joseph R. Winer PhD,Michael D. Greicius MD

2023-11-19

Abstract:Alzheimer's disease (AD) is a prevalent, progressive, and ultimately fatal neurodegenerative disorder that is defined pathologically by the accumulation of amyloid plaques and tau neurofibrillary tangles in the brain. There remains an unmet need for therapies that can halt or slow the course of AD. To address this need, the FDA has provided a mechanism, under its Accelerated Approval pathway, for potential therapeutics to be approved based in part on their ability to reduce brain amyloid. Through this pathway, two monoclonal anti-amyloid antibodies, aducanumab and lecanemab, have been approved for clinical use. More recently, another amyloid-lowering antibody, donanemab, generated a statistically significant outcome in a phase 3 clinical trial and will shortly come under FDA review. While these monoclonal antibodies are not yet routinely used in clinical practice, the series of recent positive clinical trials has fostered enthusiasm amongst some AD experts. Here, we discuss three key limitations regarding recent anti-amyloid clinical trials: (1) there is little to no evidence that amyloid reduction correlates with clinical outcome, (2) the reported efficacy of anti-amyloid therapies may be partly, or wholly, explained by functional unblinding, and (3) donanemab in its phase 3 trial had no effect on tau burden, the pathological hallmark more closely related to cognition. Taken together, these observations call into question the efficacy of anti-amyloid therapies.

Tissues and Organs
Hopes Rise for New Alzheimer’s Drug after Secondary Analysis:

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.h4048

2015-01-01

BMJ

Abstract:Data from a failed trial of a drug for Alzheimer’s disease have generated a slim hope that it was not such a failure after all. When the drug manufacturer Eli Lilly reported the results of its phase III trial of solanezumab in 2012, it looked like the end. The monoclonal antibody drug had failed to improve either cognitive or functional endpoints in patients with mild to moderate disease. Along with several other drugs that target amyloid β—the protein that forms clumps in the brains of Alzheimer’s patients—solanezumab had been a disappointment. This week, however, the company announced new results from a secondary analysis of the trial data that suggested a small, sustained effect in patients with mild disease. The original trial lasted 18 months and compared treatment against placebo, followed by a two year period in which patients on a placebo were transferred to the drug. This allowed a comparison between the early …
Promise of new Alzheimer's drug is dashed after lack of evidence.

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.i6362

2016-01-01

Abstract:The hope that a failed Alzheimer drug, solanezumab, might prove effective in patients with mild disease has proved misplaced after a phase III trial in this group of patients produced no significant benefits.The trial was the last throw of the dice for Eli Lilly in its pursuit of a blockbuster drug for Alzheimer’s disease. Solanezumab, a monoclonal antibody targeting amyloid plaques, the pathological signature of the disease, had failed an earlier phase III trial in 2012. But close examination of the results suggested that while it did not reverse the disease, it may have slowed its progress.1People given the drug earlier declined at a similar rate to those given it later, but a gap persisted between the …
Use of Lecanemab and Donanemab in the Canadian Healthcare System: Evidence, Challenges, and Areas for Future Research

Eric E. Smith,Natalie Phillips,Howard H Feldman,Michael Borrie,Aravind Ganesh,Alex Henri-Bhargava,Philippe Desmarais,Andrew Frank,AmanPreet Badhwar,Laura Barlow,Robet Bartha,Sarah Best,Jennifer Bethell,Jaspreet Bhangu,Sandra E. Black,Christian Bocti,Susan E. Bronskill,Amer M Burhan,Frederic Calon,Richard Camicioli,Barry Campbell,D. Louis M Collins,Mahsa Dadar,Mari DeMarco,Simon Ducharme,Simon Duchesne,Gillian Einstein,John D. Fisk,Jodie R Gawryluk,Linda Grossman,Zahinoor Ismail,Inbal Itzhak,Manish Joshi,Arthur Kootenay,Edeltraut Kroger,Sanjeev Kumar,Robert LaForce Jr.,Krista L. Lanctot,Meghan Lau,Linda Lee,Mario Masellis,Fadi Massoud,Sara Mitchell,Manuel Montero-Odasso,Karen Myers,Haakon B. Nygaard,Stephen Pasternak,Jody Peters,M. Natasha Rajah,Julie Robillard,Ken Rockwood,Pedro Rosa-Neto,Dallas Seitz,Jean-Paul Soucy,Shanna C. Trenaman,Cheryl Wellington,Aicha Zadem,Howard Chertkow,Canadian Consortium on Neurodegeneration in Aging

DOI: https://doi.org/10.1101/2024.11.18.24317292

2024-11-23

Abstract:Lecanemab and donanemab are monoclonal antibody therapies that remove amyloid-beta from the brain. They are the first therapies that alter a fundamental mechanism, amyloid-beta deposition, in Alzheimer disease (AD). To inform Canadian decisions on approval and use of these drugs, the Canadian Consortium on Neurodegeneration in Aging commissioned Work Groups to review evidence on the efficacy, and safety of these new therapies, as well as their projected impacts on Canadian dementia systems of care. We included persons with lived experience with Alzheimer disease in the discussion about the benefits and harms. Our review of the trial publications found strong support for statistically significant group differences, but also recognized that there are mixed views on the clinical relevance of the observed differences and the value of therapy for individual patients. The drugs are intended for persons with early AD, at a stage of mild cognitive impairment or mild dementia. If patients are treated, then confirmation of AD by positron emission tomography or cerebrospinal fluid analysis and monitoring for risk of amyloid-related imaging abnormalities was recommended, as done in the clinical trials, although it would strain Canadian resource capacity. More data are needed to determine the size of the potentially eligible treatment population in Canada.
Recent Advances in Approved, Withdrawn, Experimental and Investigational Drugs in Clinical Trials for Alzheimer’s disease

Rajlaxmi Deshpande

DOI: https://doi.org/10.23880/macij-16000174

2022-01-01

Abstract:Alzheimer’s disease (AD) is an irreversible, chronic degenerative disease that slowly destroys memory and thinking skills, and eventually destroys the ability to carry out the simplest of day-to-day routine tasks. This disease is characterised by loss of neurons and synapses in the cerebral cortex and certain subcortical regions. Presence of beta-amyloid (Aβ) plaques and neurofibrillary tangles (NFTs) in brains of the affected patients are the distinguishable characteristics of this disease. Currently, no treatment is available to stop or reverse progression of AD, though it may temporarily improve symptoms. There are four USFDA approved drugs which are helpful for symptomatic treatment in AD namely Donepezil, Rivastigmine, Galantamine and Memantine. Memantine functions as an NMDA receptor antagonist, whereas the other three drugs act by inhibiting the acetylcholinesterase enzyme (AChE) resulting in an increase in the levels of acetylcholine (ACh) in the body. In the past decades, many advancements in the current drugs as well as the experimental drugs for AD have been made and these involve structural modifications and mechanistic improvements to increase the capacity of the molecules to cross the blood brain barrier (BBB). Synthesis of 2-acetylphenol-donepezil hybrids is an example of an approach which was adopted based on MultiTarget Directed Ligand (MTDL) strategy. Recently, synthesis of salicylanilide N-alkyl carbamates was carried out and these were observed to possess higher AChE inhibiting capacity than Rivastigmine. Memogain is an inactive prodrug of galantamine which has shown improved effectiveness, fewer side effects and due to its lipophilic nature is said to penetrate the BBB where it gets cleaved into active galantamine. Huperzine A is another highly selective AChE inhibitor and is approved for use only in China though not by USFDA. Tacrine and Huperazine A were combined together to form a hybrid molecule Huprine X, which is said to possess not only potency but also higher selectivity for AChE inhibition alongside anti-Aβ properties.
How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?

Jordan Beveridge,Eileen Kaniecki,Aniketh Naidu,Bret David Silverglate,George Grossberg

DOI: https://doi.org/10.1080/14728214.2024.2304059

2024-01-14

Expert Opinion on Emerging Drugs

Abstract:Introduction Monoclonal antibodies targeting amyloid-β are the first disease-modifying treatments for Alzheimer disease to have received FDA-approval. There are three different drugs approved or pending FDA-approval: aducanumab, lecanemab, and donanemab. These three drugs are each in different stages of regulatory approval by the FDA.

pharmacology & pharmacy
Meta‐analysis of high‐clearance anti‐amyloid immunotherapies trials in early Alzheimer’s disease: A significant clinical effect but a low benefit/risk ratio

Nicolas Villain,Vincent Planche

DOI: https://doi.org/10.1002/alz.064799

2023-06-01

Abstract:In the last three years, three over four phase II or III clinical trials using high‐dose anti‐amyloid immunotherapies in early Alzheimer’s disease (AD) have turned out to be positive on clinical outcomes: aducanumab (one of two), donanemab, and lecanemab. These results contrast with the previous failures of anti‐amyloid immunotherapies. Despite different pharmacodynamic properties, these drugs share a new characteristic: the high clearance of amyloid load as measured with amyloid positron emission tomography. In the meantime, the Food and Drug Administration’s conditional approval of aducanumab has led to unprecedented scientific controversies. We used the data from the highest dose group (i.e., the groups used for approval application or ongoing phase III trials) versus placebo after 18 months of the lecanemab and donanemab phase II trials and of the two aducanumab phase III trials to perform a meta‐analysis. Regarding clinical efficacy, we analyzed the CDR‐SB, ADASCog, and MMSE data. Regarding safety, we analyzed the occurrence of any Amyloid‐Related Imaging Abnormalities (ARIA), of ARIA‐edema (ARIA‐E), of ARIA‐hemorrhage (ARIA‐H), and of symptomatic and serious ARIA. The analyses were performed using RevMan 5.4.1 and a random effect model. High‐clearance anti‐amyloid immunotherapies were shown to significantly slow down cognitive decline after 18 months as measured with CDR‐SB (weighted mean = ‐0.24 points; p = 0.04), and ADAS‐Cog (weighted mean = ‐1.25 points; p = 0.0003), but not with MMSE (weighted mean = +0.31 points; p = 0.23) when compared to placebo. In parallel, the drugs significantly increased the occurrence of any ARIA (risk ratio = 3.68; p<0.0001), of ARIA‐E (risk ratio = 13.39; p<0.0001), of ARIA‐H (risk ratio = 2.78; p = 0.0002), and of symptomatic and serious ARIA (7/1321 = 0.53% in the high dose groups versus 0/1446 in the placebo groups; risk ratio = 6.44; p = 0.04). When pooled together, the data from high‐clearance anti‐amyloid immunotherapies trials confirm a significant clinical effect after 18 months. However, this effect remains below the established minimal clinically relevant values. Safety remains an issue with 0.5% of symptomatic and serious ARIA, significantly beyond chance, despite thorough in‐trial monitoring and management. The benefit/risk ratio of this class of drugs in early AD is thus questionable after 18‐months. Identifying subgroups of better responders and the perspective of combination therapies may help improve their clinical relevance.

clinical neurology
Support for the Amyloid Cascade Hypothesis in Guiding Further Avenues of Treatment in Alzheimer's Disease

Brendan Kortjohn,Marc Nahmani

Abstract:Alzheimer’s disease currently affects 50 million individuals and is expected to increase to 152 million by 2050. Despite this prevalence, the neurodegenerative disease still has minimal treatments, and there are minimally FDA approved drugs that show any slowing in cognitive decline. One of these drugs, aducanumab (Aduhelm), attacks the amyloid-beta plaques that form in Alzheimer’s. This evidence coincides with the predominant theory in Alzheimer’s pathogenesis, the Amyloid Cascade Hypothesis (ACH). However, there are conflicting reports about whether evidence supporting aducanumab warranted FDA approval. Some scientists suggest that the underlying pathology of Alzheimer’s is via tau, which involves the accumulation of neurofibrillary tau tangles that progress to the disease’s diagnostic lesions. To determine if degrading amyloid plaques is the most beneficial path of treatment, a comprehensive literature review of current Alzheimer’s research and understanding of how the disease is treated was conducted. This review found that the ACH should remain the prevailing theory based on Alzheimer’s progression, with findings that indicate amyloid plaques are necessary to induce the phosphorylation crucial to the development of tau tangles. This data suggests that Alzheimer’s disease develops via an amyloid-induced tau-pathology. In addition, a multitude of other treatments has been shown to reduce these plaques along with aducanumab, which renews promise in using the ACH to develop treatments. Using the ACH as a guide and implementing the treatments listed in this paper, new drugs like aducanumab target the perpetrator of Alzheimer’s and may stop or reverse progression to more severe presentations of the disease.

Medicine

Alzheimer's drug with modest benefits wins backing of FDA advisers

New Alzheimer's drug clears FDA advisory vote despite unknowns

Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's

Alzheimer's drug approvals create prescribing dilemmas

1978 Donanemab in early symptomatic Alzheimer’s Disease: Efficacy and safety in TRAILBLAZER-ALZ 2, Phase 3 Randomized Clinical Trial

FDA Considers Alzheimer’s Drug Previously Abandoned for Lack of Effectiveness

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Lecanemab Questions

How donanemab data address the coverage with evidence development questions

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial

Landmark Alzheimer’s drug approval confounds research community

Donanemab in Early Alzheimer's Disease

Lecanemab's Path Forward: Navigating the Future of Alzheimer's Treatment in Europe Amidst the EMA's Rejection

Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies

Hopes Rise for New Alzheimer’s Drug after Secondary Analysis:

Promise of new Alzheimer's drug is dashed after lack of evidence.

Use of Lecanemab and Donanemab in the Canadian Healthcare System: Evidence, Challenges, and Areas for Future Research

Recent Advances in Approved, Withdrawn, Experimental and Investigational Drugs in Clinical Trials for Alzheimer’s disease

How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?

Meta‐analysis of high‐clearance anti‐amyloid immunotherapies trials in early Alzheimer’s disease: A significant clinical effect but a low benefit/risk ratio

Support for the Amyloid Cascade Hypothesis in Guiding Further Avenues of Treatment in Alzheimer's Disease